NCT05159440

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: TORL Biotherapeutics, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer

Conditions

• Advanced Solid Tumor
• Gastric Cancer
• Pancreas Cancer
• Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	TORL-2-307-MAB	monoclonal antibody

Timeline

• Start date: 2022-01-20
• Primary completion: 2024-12-15
• Completion: 2025-12-15
• First posted: 2021-12-16
• Last updated: 2024-10-22

Locations

8 sites across 2 countries: United States, South Korea

Regulatory

• FDA-regulated drug study